Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.

30 juillet 2026 mis à jour par: Swiss Cancer Institute

MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. A Phase II Trial.

Melanoma remains a common cancer with rising incidence, and despite significant improvements with immune checkpoint inhibitors (ICIs), clinical outcomes remain heterogeneous. Retrospective analyses across multiple tumor types, including melanoma, suggest that earlier daytime administration of ICIs may enhance therapeutic effectiveness, potentially due to circadian modulation of immune function. A pronounced survival benefit has been observed particularly among female patients receiving earlier infusions. This trial prospectively evaluates whether aligning ICI administration with circadian immune activity can improve outcomes in melanoma and support the development of sex-specific optimization of immunotherapy.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Description détaillée

The introduction of ICIs a decade ago revolutionized the treatment of various malignancies, particularly melanoma. Yet treatment responses are heterogenous and depend on patient characteristics such as sex and age, and tumor characteristics. The relationship between sex and ICI response in melanoma is complex and may be influenced by various factors, including the type of ICI, tumor mutation burden, presence of infiltrating immune cells, microbiome, and concomitant medications affect the immune system's ability to mount antitumor responses. While some retrospective data indicate poorer outcomes for female patients, in other real-world reports female sex is associated with better outcomes. Prospective, sex-stratified clinical studies are necessary to provide a definitive answer and to integrate sex as a critical variable in personalizing melanoma treatment strategies. Temporal variations in antibody responses and anticancer immunity after vaccination have been reported in both humans and mice. Circadian rhythms also remain an important regulator of immune cell activities. The optimal time for inducing adaptive immune responses consistently appears to be situated around or just before behavioral activity; for nocturnal mice this optimal window appears to be the afternoon, while in diurnal humans this may be the early morning. However, the optimal time of day for ICI administration is currently unknown. A retrospective single-center analysis of advanced melanoma patients showed that receiving less than 20% of the ICI infusions after 16h30 was associated with enhanced overall survival. In subgroup analyses, female patients had a significantly longer OS when less than 20% of the treatment was administered after 16h30.

Optimizing the timing of ICI therapy to target the immune system at the time of its highest sensitivity could significantly improve patient outcomes, particularly for female patients, without exposing patients to additional drugs and generating additional toxicity and costs. Given the limitations of retrospective analyses, a prospective randomized trial is essential to obtain results that could potentially change clinical practice.

Type d'étude

Interventionnel

Inscription (Estimé)

108

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

  • Suisse
      • Bellinzona, Suisse, 6500
        • Ente Ospedaliero cantonale (EOC)
        • Contact:
        • Chercheur principal:
          • Cristina Mangas de Arriba, MD
      • Bern, Suisse, 3010
        • Inselspital, Bern
        • Chercheur principal:
          • Berna Özdemir, MD
        • Contact:
      • Geneva, Suisse, 1211
        • Hôpitaux Universitaires de Genève HUG
      • Lausanne, Suisse, 1011
        • Centre Hospitalier Universitaire Vaudois (CHUV)
        • Contact:
        • Chercheur principal:
          • Sofiya MD Latifyan
      • Münsterlingen, Suisse, 8596
        • Spital Thurgau (Kantonsspital Münserlingen und Frauenfeld)
        • Chercheur principal:
          • Ioannis Metaxas, MD
        • Contact:
      • Sankt Gallen, Suisse, 9007
        • HOCH Health Ostschweiz - Kantonsspital St. Gallen
        • Contact:
        • Chercheur principal:
          • Tobias Peres, MD
      • Zurich, Suisse, 8091
        • Universitätsspital Zürich USZ
    • Canton of Fribourg
      • Fribourg, Canton of Fribourg, Suisse, 1708
        • Hfr Fribourg
        • Contact:
        • Chercheur principal:
          • Bianca Gautron Moura, MD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Written informed consent according to Swiss law and ICH GCP E6 regulations before registration and prior to any trial specific procedures.
  • Histologically confirmed unresectable cutaneous stage III or stage IV melanoma. Note: Participants with central nervous system (CNS) metastases are eligible.
  • Participants with a previously treated other malignancy are eligible, if the risk of the prior malignancy interfering with either safety or efficacy endpoints is very low.
  • Measurable or evaluable disease.
  • Age ≥ 18 years.
  • Patients deemed suitable for ICI therapy based on the local investigator's clinical assessment.
  • ECOG performance status 0-2.
  • Women of childbearing potential must use effective contraception , not be pregnant or lactating and agree not to become pregnant during trial treatment and until 5 months after the last dose of trial treatment. A negative pregnancy test before inclusion into the trial is required for all women of childbearing potential.
  • Men agree not to donate sperm or to father a child during trial treatment and until 5 months after the last dose of trial treatment.

Exclusion Criteria:

  • Prior treatment with any systemic anti-cancer therapy; with the exception of prior adjuvant anti-PD-1 or BRAF/MEK inhibitor therapy if the time from last dose to recurrence is more than 6 months.
  • Recent treatment (within 28 days prior to first dose) with any experimental drug.
  • Known history of allogeneic organ transplant.
  • Uveal or mucosal melanoma.
  • Receipt of live attenuated vaccine within 28 days prior to first dose.
  • Any concomitant drugs contraindicated for use with the trial drugs according to the approved product information.
  • Known hypersensitivity to trial drug(s) or to any component of the trial drug(s).
  • Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect participant compliance or place the participant at high risk from treatment-related complications.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: ICI Infusions 8-12 h
Participants will be randomized 1:1 to receive standard-of-care ICI therapy in an early (08:00 - 12:00) infusion time window.
Médicament: Immune Checkpoint Inhibitors

Morning administration of ICI per physician's choice, according to local practice:

Nivolumab (Opdivo®) Monotherapy - 240 mg administered intravenously every 2 weeks (Q2W)

Pembrolizumab (Keytruda®) Monotherapy

- 200 mg administered intravenously every 3 weeks (Q3W)

Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) Combination Therapy

  • Induction Phase:

    • Ipilimumab 3 mg/kg intravenously every 3 weeks (Q3W)
    • Nivolumab 1 mg/kg intravenously every 3 weeks (Q3W)
    • Administered for 4 cycles

  • Maintenance Phase:

    • Nivolumab 240 mg administered intravenously every 2 weeks (Q2W) Nivolumab + Relatlimab Fixed-Dose Combination (Opdualag®) Nivolumab 480 mg and relatlimab 160 mg administered intravenously every 4 weeks (Q4W)
Médicament: Immune Checkpoint Inhibitors

Afternooon administration of ICI per physician's choice, according to local practice:

Nivolumab (Opdivo®) Monotherapy - 240 mg administered intravenously every 2 weeks (Q2W)

Pembrolizumab (Keytruda®) Monotherapy

- 200 mg administered intravenously every 3 weeks (Q3W)

Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) Combination Therapy

  • Induction Phase:

    • Ipilimumab 3 mg/kg intravenously every 3 weeks (Q3W)
    • Nivolumab 1 mg/kg intravenously every 3 weeks (Q3W)
    • Administered for 4 cycles

  • Maintenance Phase:

    • Nivolumab 240 mg administered intravenously every 2 weeks (Q2W) Nivolumab + Relatlimab Fixed-Dose Combination (Opdualag®) Nivolumab 480 mg and relatlimab 160 mg administered intravenously every 4 weeks (Q4W)
Comparateur actif: ICI Infusions 15-18 h
Participants will be randomized 1:1 to receive standard-of-care ICI therapy in a late (15:00 - 18:00) infusion time window.
Médicament: Immune Checkpoint Inhibitors

Morning administration of ICI per physician's choice, according to local practice:

Nivolumab (Opdivo®) Monotherapy - 240 mg administered intravenously every 2 weeks (Q2W)

Pembrolizumab (Keytruda®) Monotherapy

- 200 mg administered intravenously every 3 weeks (Q3W)

Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) Combination Therapy

  • Induction Phase:

    • Ipilimumab 3 mg/kg intravenously every 3 weeks (Q3W)
    • Nivolumab 1 mg/kg intravenously every 3 weeks (Q3W)
    • Administered for 4 cycles

  • Maintenance Phase:

    • Nivolumab 240 mg administered intravenously every 2 weeks (Q2W) Nivolumab + Relatlimab Fixed-Dose Combination (Opdualag®) Nivolumab 480 mg and relatlimab 160 mg administered intravenously every 4 weeks (Q4W)
Médicament: Immune Checkpoint Inhibitors

Afternooon administration of ICI per physician's choice, according to local practice:

Nivolumab (Opdivo®) Monotherapy - 240 mg administered intravenously every 2 weeks (Q2W)

Pembrolizumab (Keytruda®) Monotherapy

- 200 mg administered intravenously every 3 weeks (Q3W)

Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) Combination Therapy

  • Induction Phase:

    • Ipilimumab 3 mg/kg intravenously every 3 weeks (Q3W)
    • Nivolumab 1 mg/kg intravenously every 3 weeks (Q3W)
    • Administered for 4 cycles

  • Maintenance Phase:

    • Nivolumab 240 mg administered intravenously every 2 weeks (Q2W) Nivolumab + Relatlimab Fixed-Dose Combination (Opdualag®) Nivolumab 480 mg and relatlimab 160 mg administered intravenously every 4 weeks (Q4W)

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Progression-free survival (PFS)
Délai: From randomization to Progressive Desease or death, up to 6 years
Progression-free survival (PFS), defined as time from randomization to progression according to local assessment or death. Participants not experiencing an event will be censored at the date of the last available assessment before initiation of a new anti-cancer treatment, if any.
From randomization to Progressive Desease or death, up to 6 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Overall survival (OS)
Délai: From randomization to death, up to 6 year
OS is defined as the time from randomization until death due to any cause. Participants not experiencing an event will be censored at the last date they were known to be alive.
From randomization to death, up to 6 year
Objective response rate (ORR)
Délai: At the end of trial treatment, up to 4 years from registration
Objective response rate (ORR) Objective response is defined as any complete response (CR) or partial response (PR) according to local assessment achieved during treatment. Any participant with CR or PR as best observed response during treatment will be considered as a success; otherwise, they will be considered as a failure. Participants without any tumor assessment, or with non-evaluable response (NE) during treatment, will be considered as failures for this endpoint.
At the end of trial treatment, up to 4 years from registration

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Swiss Cancer Institute

Les enquêteurs

  • Chaise d'étude: Berna Özdemir, MD PhD, Insel Gruppe AG, University Hospital Bern

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 septembre 2026

Achèvement primaire (Estimé)

1 juin 2030

Achèvement de l'étude (Estimé)

1 juin 2032

Dates d'inscription aux études

Première soumission

1 mai 2026

Première soumission répondant aux critères de contrôle qualité

1 mai 2026

Première publication (Réel)

7 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

31 juillet 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

30 juillet 2026

Dernière vérification

1 juillet 2026

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • SCI-004_MELCHRONO

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner